Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Inclusion Criteria: * Age \>=18 years, either sex, any race. * Eastern Cooperative Oncology Group performance status of 0, 1, or 2. * There must be no known standard therapy, or disease must be refractory to standard therapy * Adequate hematologic, renal, and hepatic organ function and laboratory parameters * For advanced solid tumors, non-Hodgkin's lymphoma, or multiple myeloma: * Participants must have histologically proven solid tumors, non-Hodgkin's lymphoma, or multiple myeloma. * Evaluable malignancy must be present by computed tomography or magnetic resonance imaging, obtained within 4 weeks prior to the start of treatment with SCH 727965. * Subjects with multiple myeloma must have measurable disease defined as: * Serum monoclonal protein greater than 0.5 g/dL or urine light chain excretion of greater than 0.2 g/24-hour obtained within 4 weeks prior to the start of treatment. * Participants with lower M protein values or nonsecretory myeloma are eligible if measurable disease can be established within 4 weeks prior to start of treatment, such as: * serum free light chain ratio greater than 5 times the normal ratio limit; and/or * measurable soft tissue plasmacytoma greater than 2 cm, by either physical examination and/or applicable radiographs; and/or * bone marrow involvement greater than 30%. * For B-cell chronic lymphocytic leukemia (B-CLL): * Diagnosis of B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria or a histological diagnosis of small lymphocytic lymphoma. * Disease must be evaluable according to NCI-WG response criteria. Exclusion Criteria: * Symptomatic brain metastases or primary central nervous system malignancy. * Previous radiation therapy to \>25% of the total bone marrow. * Previous treatment with SCH 727965. * Known HIV infection.